Argenx Unveils Major New Clinical Data on VYVGART at AAN 2026
Argenx announces through a press release that it will present new clinical data at the American Academy of Neurology (AAN) annual conference in April 2026, focusing on its VYVGART treatments and development phase candidates in the field of autoimmune diseases.
Comprehensive Clinical Results to be Showcased
During the AAN conference in Chicago (April 18-22, 2026), the immunology group will display clinical results for VYVGART (available in intravenous and subcutaneous Hytrulo formulations) as well as for its drug candidates empasiprubart and adimanebart. Argenx indicates that the data presented will include Phase 3 results in ocular myasthenia gravis, data supporting the use of VYVGART in patients with generalized myasthenia gravis without detectable anti-acetylcholine receptor antibodies, and in adolescents. The group also plans to present analyses on the long-term safety and efficacy of VYVGART in clinical and real-life settings, as well as data on the candidate adimanebart in congenital myasthenic syndromes.
Advancing the Pipeline with New Mechanisms of Action
Argenx continues to advance its pipeline with two new mechanisms of action, aiming to develop precision therapies for multiple neurological diseases. In the field of chronic inflammatory demyelinating polyneuropathy (CIDP), the company will highlight results from post hoc analyses and data from the neurofilament light chain biomarker. For the candidate adimanebart, Argenx plans to share results from a Phase 1b trial in patients with congenital myasthenic syndromes linked to a DOK7 variation, accompanied by a proof of concept demonstration. The group emphasizes its commitment to expanding access to targeted treatment options for as many myasthenia gravis patients as possible.
